3 completed. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 3 |
Follow Andrew Carr: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis dolutegravir 50 mg (one tablet daily), emtricitabine-tenofovir 300/200 mg (one tablet daily) - Human Immunodeficiency Virus | Phase 4 | Completed | Andrew Carr | 100 | 2014-08-01 | 2016-05-27 |
| Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men. Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg - HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men | Phase 4 | Completed | Andrew Carr | 100 | 2012-12-01 | 2015-01-12 |
| Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men Raltegravir - HIV Prevention, HIV Infections | Phase 4 | Completed | Andrew Carr | 120 | 2010-07-01 | 2014-04-17 |
Acquired Immunodeficiency Syndrome (1) · HIV Infections (1)
Tenofovir (2) · Emtricitabine (1) · Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1) · Raltegravir Potassium (1) · Rilpivirine (1) · dolutegravir (1)
Australia (3)
Anna McNulty, MBBS, FAChSHM (1) · Phillip Read, MBBS, FAChSHM (1) · Robert Fielden, RN (1)